康方生物(09926.HK) 公布,与济川药业(600566.SH) 签订独占性商业化权益协议,据此,济川药业获授权在中国(不包括香港、澳门及台湾)拥有公司自主开发并已获批上市的伊喜宁(伊努西单抗注射液)独家商业化权益。本次合作,公司将获得8,000万人民币授权费,以及最高不超过1,000万人民币的里程碑付款。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-02-03 16:25。...
Source Link康方生物(09926.HK) 公布,与济川药业(600566.SH) 签订独占性商业化权益协议,据此,济川药业获授权在中国(不包括香港、澳门及台湾)拥有公司自主开发并已获批上市的伊喜宁(伊努西单抗注射液)独家商业化权益。本次合作,公司将获得8,000万人民币授权费,以及最高不超过1,000万人民币的里程碑付款。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-02-03 16:25。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.